Top analysts on stock perps · Analyst
Leah R. Cann (Brookline Capital Markets): analyst track record on stock perps
Leah R. Cann of Brookline Capital Markets on companies with stock perpetual futures: star rating, success rate, price-target accuracy, current calls and the measured perp reaction after each rating.
Stars0.7★
Success38%
Excess return-1.5%
rank#10,864
Ratings439
ratings on stock perps12
Track record
TipRanks data via FMP| 12 months | 3 years | |
|---|---|---|
| Ratings | 3 | 34 |
| Stock | 3 | 14 |
| Buy / hold / sell | 2 / 1 / 0 | 30 / 4 / 0 |
| Upgrades / downgrades / initiations | 0 / 1 / 1 | 0 / 4 / 3 |
| Price targets hit / missed | 0 / 2 (0%) | 10 / 19 (34%) |
| Avg. return after a rating (TipRanks) | -66.1% | -34.2% |
| Best / worst call | -42.2% / -90.1% | +76.7% / -100.0% |
After buy calls: not enough measured cases yet
Current calls on stock perps
| Stock | Call | Target | vs last close | Date |
|---|---|---|---|---|
| $RVMD Revolution Medicines, Inc. | Buy · Initiated | $318 | +68.6% | Sep 28, 2026 |
Recent ratings
- Sep 28, 2026 $RVMD: Initiated · Buy · $318 · article
- Sep 28, 2026 $RVMD: Initiated · Buy · $318 · article
- Sep 23, 2025 $MRNA: Reiterated · Buy · $198 · article
- Jul 10, 2025 $MRNA: Reiterated · Buy · $198 · article
- May 21, 2025 $MRNA: Reiterated · Buy · $198 · article
- Mar 31, 2025 $MRNA: Reiterated · Buy · $212 · article
- Dec 26, 2024 $EXEL: Maintained · Buy · $40.00 · article
- Dec 23, 2024 $EXEL: Initiated · Buy · $40.00 · article
- Sep 13, 2024 $MRNA: Maintained · Buy · $238 · article
- Sep 3, 2024 $MRNA: Reiterated · Buy · $310 · article
- Jun 10, 2024 $MRNA: Reiterated · Buy · $310 · article
- Jan 2, 2024 $MRNA: Maintained · Buy · $310 · article
Leah R. Cann0.7★ · 38% success · -1.5% excess return · TipRanks data via FMP · Source headlines via TheFly/StreetInsider (FMP). Reaction = venue-median perp move after our detection — an observation, not investment advice.